Erlotinib companion diagnostic - Roche Diagnostics

Drug Profile

Erlotinib companion diagnostic - Roche Diagnostics

Alternative Names: cobas EGFR Mutation Test v2; cobasEGFR Mutation Test

Latest Information Update: 03 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Diagnostics
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 01 Jun 2016 US FDA approves Erlotinib companion diagnostic for use with plasma samples for Non-small cell lung cancer (Diagnosis) in USA
  • 13 Nov 2015 The US FDA approves cobas® EGFR Mutation Test v2 for use with tumours samples for Non-small cell lung cancer (diagnosis) in USA
  • 14 May 2013 Registered for Non-small cell lung cancer (diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top